{"name":"Biotec Pharmacon ASA","slug":"biotec-pharmacon-asa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SBG","genericName":"SBG","slug":"sbg","indication":"Prevention of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Soluble beta-glucan (SBG)","genericName":"Soluble beta-glucan (SBG)","slug":"soluble-beta-glucan-sbg","indication":"Immune support and infection prevention in immunocompromised patients","status":"phase_3"}]}],"pipeline":[{"name":"SBG","genericName":"SBG","slug":"sbg","phase":"phase_3","mechanism":"SBG is a bone morphogenetic protein (BMP) antagonist that inhibits heterotopic ossification by blocking BMP signaling pathways.","indications":["Prevention of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP)"],"catalyst":""},{"name":"Soluble beta-glucan (SBG)","genericName":"Soluble beta-glucan (SBG)","slug":"soluble-beta-glucan-sbg","phase":"phase_3","mechanism":"Soluble beta-glucan activates innate immune cells to enhance immune response and reduce infection risk.","indications":["Immune support and infection prevention in immunocompromised patients","Adjunctive therapy for respiratory tract infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQc3ZhR2FvdHY2OS1ISkhGR2JDXzhKZWNaSmhpblJLcjdCbHdWSkFVZk5pR3htcm9ETnVSUkRJbVpJSHlUSFVjN0hOUTVQTzRaQ2dPTXI2STdzeWMwN3JGNS1vSXcxTHZpU3Q1c2pxNm92ck1OOGZlT2J2Z0ZVd0pKanY2T2hOTWtWRFVwZmhn?oc=5","date":"2024-02-09","type":"pipeline","source":"openPR.com","summary":"Beta Glucan Market Size, Share, Price, Trends, Growth, - openPR.com","headline":"Beta Glucan Market Size, Share, Price, Trends, Growth,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOQU4wdlRCbExqTURLaWpTbHNPMkp3YklCSFV6U04tLVRVOHpUTVR6Y3IxTnpkTTBMUU9zM3V1REdEY3JsTnUzMTFWUHhIQkx1M0o3cmstMFhRMzZrUWQ2dG9mX2p2SnI5MGxuT1pNdzR2Sk1JTkJGRVZFTGN6RndIdElvWEc2TjBZZDh4VGg4Qm9qUDNSZElGblJKNHRPdWl2d3g2d3BqaUJnRlZiUEx3dm9iMDZIMGlpSzF0WF9mUW5hZHRpOWZRZ0paSkVidzRBcXg4?oc=5","date":"2019-05-14","type":"pipeline","source":"Issuewire","summary":"Beta-Glucan Market Analysis and Outlook to 2025 Key players Tate & Lyle PLC (U.K), Biothera Pharmace - Issuewire","headline":"Beta-Glucan Market Analysis and Outlook to 2025 Key players Tate & Lyle PLC (U.K), Biothera Pharmace","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}